NK 细胞治疗血液系统恶性肿瘤的研究进展：NK 细胞来源、持久性和肿瘤靶向性。
Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting.
机构信息
Division of Hematology, Oncology, and Transplantation, University of Minnesota, 420 Delaware St, Minneapolis, MN, United States of America.
Division of Hematology, Oncology, and Transplantation, University of Minnesota, 420 Delaware St, Minneapolis, MN, United States of America.
出版信息
Blood Rev. 2023 Jul;60:101073. doi: 10.1016/j.blre.2023.101073. Epub 2023 Mar 12.
Abstract
Natural Killer (NK) cells yield promise in therapy of hematologic malignancies. The clinical experience with adoptively transferred allogeneic NK cells over past two decades has revealed safety and minimal risk of CRS or ICANS. Unlike T cells which have to be genetically altered to avoid graft vs host disease (GVHD), HLA mismatched NK cells can be infused without GVHD risk. This makes them ideal for the development of off-the-shelf products. In this review we focus on NK biology relevant to the cancer therapy, the trajectory of NK therapeutics for leukemia, lymphoma, and myeloma; and advantages of the NK cell platform. We will also discuss novel methods to enhance NK cell targeting, persistence, and function in the tumor microenvironment. The future of NK cell therapy depends on novel strategies to realize these qualities.
摘要
自然杀伤 (NK) 细胞在血液系统恶性肿瘤的治疗中具有广阔的前景。过去二十年来，过继性输注同种异体 NK 细胞的临床经验表明，其具有安全性，发生细胞因子释放综合征 (CRS) 或免疫效应细胞相关神经毒性综合征 (ICANS) 的风险极小。与必须经过基因改造以避免移植物抗宿主病 (GVHD) 的 T 细胞不同，HLA 不相合的 NK 细胞可以输注而不会有 GVHD 的风险。这使得它们成为现成产品开发的理想选择。在这篇综述中，我们重点关注与癌症治疗相关的 NK 生物学、NK 细胞疗法在白血病、淋巴瘤和骨髓瘤中的发展轨迹，以及 NK 细胞平台的优势。我们还将讨论增强 NK 细胞在肿瘤微环境中的靶向性、持久性和功能的新方法。NK 细胞治疗的未来取决于实现这些特性的新策略。
相似文献
1
Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting.NK 细胞治疗血液系统恶性肿瘤的研究进展：NK 细胞来源、持久性和肿瘤靶向性。
Blood Rev. 2023 Jul;60:101073. doi: 10.1016/j.blre.2023.101073. Epub 2023 Mar 12.
2
Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.单倍体相合自然杀伤细胞在异基因干细胞移植前输注用于髓系恶性肿瘤：一项I期试验
Biol Blood Marrow Transplant. 2016 Jul;22(7):1290-1298. doi: 10.1016/j.bbmt.2016.04.009. Epub 2016 Apr 16.
3
Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies.嵌合抗原受体自然杀伤细胞疗法在克服难治性血液系统恶性肿瘤方面的最新进展。
Hematol Oncol. 2021 Feb;39(1):11-19. doi: 10.1002/hon.2802. Epub 2020 Sep 21.
4
NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.自然杀伤细胞通过增强免疫/肿瘤细胞簇的形成和改善嵌合抗原受体 T 细胞的适应性来增强 CAR-T 细胞的抗肿瘤疗效。
J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2021-002866.
5
Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.基因工程与人类自然杀伤细胞的扩增用于 CAR 增强免疫治疗血液系统恶性肿瘤。
Front Immunol. 2022 Apr 7;13:847008. doi: 10.3389/fimmu.2022.847008. eCollection 2022.
6
CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.嵌合抗原受体自然杀伤细胞（CAR-NK）用于肿瘤免疫治疗：临床转化与未来前景。
Cancer Lett. 2020 Mar 1;472:175-180. doi: 10.1016/j.canlet.2019.11.033. Epub 2019 Nov 29.
7
CAR-NK cell in cancer immunotherapy; A promising frontier.嵌合抗原受体自然杀伤（CAR-NK）细胞在癌症免疫治疗中的应用：一个充满希望的前沿领域。
Cancer Sci. 2021 Sep;112(9):3427-3436. doi: 10.1111/cas.14993. Epub 2021 Jul 7.
8
Next Generation Natural Killer Cells for Cancer Immunotherapy.下一代自然杀伤细胞用于癌症免疫治疗。
Front Immunol. 2022 Jun 2;13:886429. doi: 10.3389/fimmu.2022.886429. eCollection 2022.
9
CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022.嵌合抗原受体自然杀伤细胞疗法治疗血液系统恶性肿瘤：2022 年ASH 年会最新进展。
J Hematol Oncol. 2023 Apr 7;16(1):35. doi: 10.1186/s13045-023-01435-3.
10
NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles.自然杀伤细胞作为过继细胞疗法治疗血液系统恶性肿瘤：优势与障碍。
Semin Hematol. 2020 Oct;57(4):175-184. doi: 10.1053/j.seminhematol.2020.10.004. Epub 2020 Oct 26.
引用本文的文献
1
Animal Venoms as Potential Antitumor Agents Against Leukemia and Lymphoma.动物毒液作为对抗白血病和淋巴瘤的潜在抗肿瘤剂
Cancers (Basel). 2025 Jul 14;17(14):2331. doi: 10.3390/cancers17142331.
2
Precision sniper for solid tumors: CAR-NK cell therapy.实体瘤的精准狙击：CAR-NK细胞疗法。
Cancer Immunol Immunother. 2025 Jul 24;74(9):275. doi: 10.1007/s00262-025-04106-z.
3
Targeting SUMOylation triggers interferon-ß-dependent activation of patient and allogenic Natural Killer cells in preclinical models of Acute Myeloid Leukemia.在急性髓系白血病的临床前模型中，靶向SUMO化可触发患者及同种异体自然杀伤细胞的干扰素-β依赖性激活。
Mol Cancer Ther. 2025 Jul 15. doi: 10.1158/1535-7163.MCT-25-0504.
4
Engineered iPSC-derived natural killer cells: recent innovations in translational innate anti-cancer immunotherapy.工程化诱导多能干细胞衍生的自然杀伤细胞：转化性先天性抗癌免疫疗法的最新创新
Clin Transl Immunology. 2025 Jul 10;14(7):e70045. doi: 10.1002/cti2.70045. eCollection 2025.
5
Histamine dihydrochloride and low-dose interleukin-2 in an emerging landscape of relapse prevention in acute myeloid leukemia.盐酸组胺与低剂量白细胞介素-2在急性髓系白血病复发预防新领域中的应用
Ther Adv Hematol. 2025 Jun 28;16:20406207251351086. doi: 10.1177/20406207251351086. eCollection 2025.
6
Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation.通过细胞因子刺激增强运动动员的供体淋巴细胞输注，用于预防和治疗异基因造血细胞移植后的白血病复发。
Front Immunol. 2025 Jun 12;16:1563972. doi: 10.3389/fimmu.2025.1563972. eCollection 2025.
7
IPSC‑derived NK cells for immunotherapy and therapeutic perspective (Review).用于免疫治疗的诱导多能干细胞衍生自然杀伤细胞及其治疗前景（综述）
Mol Med Rep. 2025 Aug;32(2). doi: 10.3892/mmr.2025.13587. Epub 2025 Jun 6.
8
Nanomaterial assisted natural killer cell therapy.纳米材料辅助自然杀伤细胞疗法。
Front Immunol. 2025 May 5;16:1558701. doi: 10.3389/fimmu.2025.1558701. eCollection 2025.
9
Identifying acute myeloid leukemia subtypes based on pathway enrichment.基于通路富集识别急性髓系白血病亚型。
Front Pharmacol. 2025 Mar 21;16:1557112. doi: 10.3389/fphar.2025.1557112. eCollection 2025.
10
FT538, iPSC-derived NK cells, enhance AML cell killing when combined with chemotherapy.FT538，即诱导多能干细胞衍生的自然杀伤细胞，与化疗联合使用时可增强对急性髓系白血病细胞的杀伤作用。
J Cell Mol Med. 2025 Jan;29(1):e70169. doi: 10.1111/jcmm.70169.
本文引用的文献
1
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape.基于 KIR 的抑制性 CAR 可克服 CAR-NK 细胞 trogocytosis 介导的自相残杀和肿瘤逃逸。
Nat Med. 2022 Oct;28(10):2133-2144. doi: 10.1038/s41591-022-02003-x. Epub 2022 Sep 29.
2
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.苯达莫司汀在难治性或复发性大 B 细胞淋巴瘤患者中用于替西奥仑赛之前是安全有效的。
Ann Oncol. 2022 Sep;33(9):916-928. doi: 10.1016/j.annonc.2022.05.521. Epub 2022 Jun 9.
3
Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.双特异性抗体介导的 NKG2D-CAR 自然杀伤细胞重定向促进双重靶向并增强抗肿瘤活性。
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-002980.
4
Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy.利用适应性自然杀伤细胞的特性生成诱导多能干细胞衍生的自然杀伤细胞，以增强免疫疗法。
Cell Stem Cell. 2021 Dec 2;28(12):2062-2075.e5. doi: 10.1016/j.stem.2021.08.013. Epub 2021 Sep 14.
5
Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia.活化自然杀伤细胞预测高危 B 细胞和 T 细胞急性淋巴细胞白血病的不良临床预后。
Blood. 2021 Oct 21;138(16):1465-1480. doi: 10.1182/blood.2020009871.
6
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30 Malignancies.将 AFM13（一种双特异性 CD30/CD16 抗体）与细胞因子激活的血液和脐带血来源的 NK 细胞联合使用，可促进针对 CD30 恶性肿瘤的类似 CAR 的反应。
Clin Cancer Res. 2021 Jul 1;27(13):3744-3756. doi: 10.1158/1078-0432.CCR-21-0164. Epub 2021 May 13.
7
Early Adaptive Natural Killer Cell Expansion Is Associated with Decreased Relapse After Autologous Transplantation for Multiple Myeloma.早期适应性自然杀伤细胞扩增与多发性骨髓瘤自体移植后复发减少相关。
Transplant Cell Ther. 2021 Apr;27(4):310.e1-310.e6. doi: 10.1016/j.jtct.2020.10.023. Epub 2020 Dec 17.
8
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.双等位基因 BCMA 缺失导致多发性骨髓瘤患者对 CAR T 细胞治疗产生耐药。
Nat Commun. 2021 Feb 8;12(1):868. doi: 10.1038/s41467-021-21177-5.
9
Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma.自体移植后多次输注体外扩增的单倍体同种异体自然杀伤细胞进行细胞免疫治疗多发性骨髓瘤患者。
Cytotherapy. 2021 Apr;23(4):329-338. doi: 10.1016/j.jcyt.2020.09.009. Epub 2020 Nov 29.
10
Umbilical Cord Blood and iPSC-Derived Natural Killer Cells Demonstrate Key Differences in Cytotoxic Activity and KIR Profiles.脐带血和 iPSC 衍生自然杀伤细胞在细胞毒性活性和 KIR 谱方面表现出关键差异。
Front Immunol. 2020 Oct 15;11:561553. doi: 10.3389/fimmu.2020.561553. eCollection 2020.
Zotero 插件